These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 37799715)

  • 21. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression.
    Huang L; Gainkam LO; Caveliers V; Vanhove C; Keyaerts M; De Baetselier P; Bossuyt A; Revets H; Lahoutte T
    Mol Imaging Biol; 2008; 10(3):167-75. PubMed ID: 18297364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
    Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
    Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanobodies as tools for in vivo imaging of specific immune cell types.
    De Groeve K; Deschacht N; De Koninck C; Caveliers V; Lahoutte T; Devoogdt N; Muyldermans S; De Baetselier P; Raes G
    J Nucl Med; 2010 May; 51(5):782-9. PubMed ID: 20395332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 28. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.
    De Vos J; Mathijs I; Xavier C; Massa S; Wernery U; Bouwens L; Lahoutte T; Muyldermans S; Devoogdt N
    Mol Imaging Biol; 2014 Oct; 16(5):690-8. PubMed ID: 24687730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
    Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
    Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis.
    Put S; Schoonooghe S; Devoogdt N; Schurgers E; Avau A; Mitera T; D'Huyvetter M; De Baetselier P; Raes G; Lahoutte T; Matthys P
    J Nucl Med; 2013 May; 54(5):807-14. PubMed ID: 23447654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ImmunoPET imaging of TIGIT in the glioma microenvironment.
    Vincze SR; Jaswal AP; Frederico SC; Nisnboym M; Li B; Xiong Z; Sever RE; Sneiderman CT; Rodgers M; Day KE; Latoche JD; Foley LM; Hitchens TK; Frederick R; Patel RB; Hadjipanayis CG; Raphael I; Nedrow JR; Edwards WB; Kohanbash G
    Sci Rep; 2024 Mar; 14(1):5305. PubMed ID: 38438420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging of Tumor Spheroids, Dual-Isotope SPECT, and Autoradiographic Analysis to Assess the Tumor Uptake and Distribution of Different Nanobodies.
    Beltrán Hernández I; Rompen R; Rossin R; Xenaki KT; Katrukha EA; Nicolay K; van Bergen En Henegouwen P; Grüll H; Oliveira S
    Mol Imaging Biol; 2019 Dec; 21(6):1079-1088. PubMed ID: 30859470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
    Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
    Front Immunol; 2022; 13():828319. PubMed ID: 35273608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
    Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
    Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural and functional characterization of a monoclonal antibody blocking TIGIT.
    Jeong BS; Nam H; Lee J; Park HY; Cho KJ; Sheen JH; Song E; Oh M; Lee S; Choi H; Yang JE; Kim M; Oh BH
    MAbs; 2022; 14(1):2013750. PubMed ID: 35090381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.
    Li L; Lin X; Wang L; Ma X; Zeng Z; Liu F; Jia B; Zhu H; Wu A; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3735-3749. PubMed ID: 37382662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.